P225 Pharmacokinetics/pharmacodynamics and safety of AMG 181, a fully human anti-α 4 β 7 antibody for treating inflammatory bowel diseases (IBD)

P225 Pharmacokinetics/pharmacodynamics and safety of AMG 181, a fully human anti-a 4 b 7 antibody for treating inflammatory bowel diseases (IBD) W.-J. Pan1 *, B. Sullivan2, C. Evangelista2, D. Doherty1, C.-Y. Tam1, S. Patel1, P. Prince1, K. Reynhardt3, W. Rees4, H. Hsu5, K. Zhou6, W. Gu7, M. Yen8, C. Haller9, S. Dodson10, Z. Yu10, L. Wienkers1, D. Borie11. 1Amgen Inc., Pharmacokinetics and Drug Metabolism, Seattle, United States, 2Amgen Inc., Clinical Immunology, Thousand Oaks, United States, 3Amgen Inc., Clinical Immunology, Seattle, United States, 4Amgen Inc., Molecular Sciences and Computational Biology, Seattle, United States, 5Amgen Inc., Inflammation, Thousand Oaks, United States, 6Amgen Inc., Biostatistics, San Francisco, United States, 7Amgen Inc., Biostatistics, Thousand Oaks, United States, 8Parexel Early Phase, California Clinical Trials Trials Medical Group, Glendale, United States, 9Amgen Inc., Regulatory, San Francisco, United States, 10Amgen Inc., Early Development, Thousand Oaks, United States, 11Amgen Inc., Inflammation Clinical Research, Thousand Oaks, United States